The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042, November 2007

Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study

  • Søren E. Pedersen, MD, DMSc

      Affiliations

    • Department of Pediatrics, University of Southern Denmark, Pediatric Research Unit, Kolding Hospital, Kolding, Denmark
    • Corresponding Author InformationReprint requests: Søren E. Pedersen, MD, DMSc, University of Southern Denmark, Department of Pediatrics, Pediatric Research Unit, Kolding Hospital, Kolding DK 6000, Denmark.
  • ,
  • Eric D. Bateman, MD

      Affiliations

    • Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • ,
  • Jean Bousquet, MD

      Affiliations

    • Hôpital Arnaud de Villeneuve, Montpellier, France
  • ,
  • William W. Busse, MD

      Affiliations

    • Department of Medicine, University of Wisconsin–Madison Medical School, Madison, Wis
  • ,
  • Sally Yoxall, MSc

      Affiliations

    • GlaxoSmithKline, Greenford, Middlesex, United Kingdom
  • ,
  • Tim J. Clark, MD

      Affiliations

    • National Heart and Lung Institute, Imperial College, London, United Kingdom
  • ,
  • Gaining Optimal Asthma controL Steering Committee and Investigators

Received 15 February 2007; received in revised form 5 July 2007; accepted 12 July 2007. published online 12 October 2007.

Background

During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for 1 year. Approximately two thirds of patients achieved well-controlled (WC) asthma, and one third continued to have asthma that was not well controlled (NWC).

Objective

This analysis aimed to (1) identify factors influencing treatment response and (2) assess the clinical benefits of SFC and FP in patients with NWC asthma.

Methods

Logistic regression analysis was used to investigate whether covariates influenced the achievement of at least WC asthma in the study population. In patients with NWC asthma, predefined criteria were used to assess improvements in 6 clinical outcomes.

Results

Factors affecting the probability of having NWC asthma included smoking status (current vs never: odds ratio [OR], 2.757; 95% CI, 2.061−3.689; P < .0001; former vs never: OR, 1.274; 95% CI, 1.031−1.574; P = 0.0273), sex (women vs men: OR, 0.652; 95% CI, 0.527–0.806; P < .0001), history of inhaled corticosteroid use (no history vs history: OR, 0.546; 95% CI, 0.437−0.683; P < .0001), and treatment (FP vs SFC: OR, 1.972; 95% CI, 1.686–2.308; P < .0001). Of patients with NWC asthma, 86% to 96% showed improvements in 1 or more clinical outcomes.

Conclusion

It is imperative for good asthma control that patients stop smoking. Patients who did not have at least WC asthma demonstrated clinical improvements in individual asthma outcomes.

Clinical implications

Although not all patients can achieve guideline-defined control, long-term treatment with SFC or FP is associated with clinical improvements in nearly all patients, regardless of smoking history or inhaled corticosteroid use.

Key words: Asthma, salmeterol/fluticasone propionate combination, asthma control, treatment response, smoking

Abbreviations used: AQLQ, Asthma quality of life questionnaire, BDP, Beclomethasone dipropionate, FP, Fluticasone propionate, GOAL, Gaining Optimal Asthma controL, GR, Glucocorticoid receptor, ICS, Inhaled corticosteroid, NWC, Not well controlled, OR, Odds ratio, PEF, Peak expiratory flow, PEFR, Peak expiratory flow rate, SFC, Salmeterol/fluticasone propionate combination, TC, Total control, WC, Well controlled

 

 The funding for the original Gaining Optimal Asthma controL study (GSK study no. CCC3456788) from which these data were derived was from GlaxoSmithKline R&D.

 Disclosure of potential conflict of interest: S. E. Pedersen has consulting arrangements with GlaxoSmithKline, Nycomed, and Merck and has received grant support from GlaxoSmithKline, Nycomed, and AstraZeneca. E. D. Bateman has consulting arrangements with GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Altana, Kyowa Hakko, Hoffman La Roche, Almirall, and Merck and is on the speakers' bureau for GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Altana. J. Bousquet has consulting arrangements with and has received grant support from GlaxoSmithKline. W. W. Busse has consulting arrangements with Genentech/Novartis, Isis, GlaxoSmithKline, Altana, Wyeth, Pfizer, Dynavax, and Centocor; has received grant support from Novartis, Wyeth, Dynavax, and Centocor; and is on the speakers' bureau for GlaxoSmithKline, Novartis, Merck, and AstraZeneca. S. Yoxall is employed by GlaxoSmithKline. T. J. Clark has consulting arrangements with GlaxoSmithKline.

PII: S0091-6749(07)01387-5

doi:10.1016/j.jaci.2007.07.016

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 5 , Pages 1036-1042, November 2007